Log In
Print this Print this

PathFinder TG molecular diagnostic assay for pancreatic cancer

  Manage Alerts
Collapse Summary General Information
Company PDI Inc.
DescriptionAssay that uses loss of heterozygosity (LOH) markers, oncogene mutations and DNA content abnormalities to stratify patients according to their risk of progression to cancer
Molecular Target
Mechanism of Action 
Therapeutic ModalityDiagnostics
Latest Stage of DevelopmentMarketed
Standard IndicationCancer, Diagnostic
Indication DetailsDiagnose risk of pancreatic cancer
Regulatory Designation


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today